Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2,
27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with
Cyclophosphamide 2 gm/m2, Dexamethasone and G-CSF